Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho to Fund Research Projects to Improve Clinical Research Infrastructure
November 7, 2005
- JMA Pamphlet Questions Need to Control Healthcare Spending
November 7, 2005
- R&D NEWS IN BRIEF
November 7, 2005
- SURVEY 2 articles
November 7, 2005
- IC Tag Commercialization Research Project Invites Members
November 7, 2005
- SymBio to Address "Underserved Therapeutic Areas"
November 7, 2005
- NEW PRODUCTS
November 7, 2005
- Drug Companies to Enjoy Good Results in 1st Half
November 7, 2005
- SEMINAR
November 7, 2005
- Eisai Licenses Vaccine Adjuvant to Sanofi Pasteur
November 7, 2005
- Kyorin Licenses OAB Treatment to LG Life Sciences of South Korea
November 7, 2005
- Pharma Industry Has Steadily Increased Added Value: OPIR Report
November 7, 2005
- MREAC to Review MR Certification, Accreditation Systems
November 7, 2005
- BUSINESS NEWS IN BRIEF
November 7, 2005
- Korosho's Healthcare Reform Proposals Criticized by Prefectural Governor
November 7, 2005
- REGULATORY NEWS IN BRIEF
November 7, 2005
- the 6th Kitasato University-Harvard School of Public Health Symposium
November 7, 2005
- Japan Lags Behind Other Countries in Terms of Access to New Drugs: OPIR Report
November 7, 2005
- Strengthen Consultation System to Promote Participation in Int'l Clinical Trials: Dr Doi of PMDA
November 7, 2005
- Pfizer Seeks Preliminary Injunction for Return of Data on Amlodipine: DSP
October 31, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…